GLP-1 plus glucagon, in phase 3 for obesity and liver disease at the same time. The only compound in this class with that dual bet.
Survodutide pairs GLP-1 appetite suppression with glucagon-driven energy expenditure. It is in the phase 3 SYNCHRONIZE program for obesity, and separately in trials for MASH (metabolic liver disease). The liver angle is what makes it interesting: glucagon acts directly on liver fat metabolism, so the drug has a plausible second mechanism that has nothing to do with weight loss.
| Program | Indication | Phase | Status |
|---|---|---|---|
| SYNCHRONIZE-1 | Obesity | Phase 3 | Underway |
| SYNCHRONIZE-2 | Obesity | Phase 3 | Underway |
| MASH program | Liver disease | Phase 2/3 | Underway |
Against retatrutide's triple mechanism, survodutide is the simpler glucagon bet: two receptors instead of three. Against mazdutide, it is earlier (phase 3 underway vs approved in China) but broader (two indications). No headline phase 3 weight-loss number exists yet, which is why this page is shorter than the others. When SYNCHRONIZE reads out, it gets updated.
No. Survodutide is investigational, in the phase 3 SYNCHRONIZE program for obesity. It is also being studied for metabolic liver disease (MASH).
Survodutide hits two receptors (GLP-1 + glucagon). Retatrutide hits three (adds GIP). Survodutide is the simpler bet on the glucagon strategy.
Glucagon directly affects liver fat metabolism, which gives survodutide a plausible edge in MASH independent of weight loss. That dual indication is unusual in this class.
The SYNCHRONIZE-1 and SYNCHRONIZE-2 trials are underway. No approved status anywhere yet.
All compounds are sold strictly as laboratory research chemicals, not for human consumption. Trial figures are mean changes in the cited trial populations.
